DTIL.US Precision BioSciences Inc

Healthcare Biotechnology USA Stocks
7.57 USD
Close of Nov 14, 2026
3.53 11.29
Market cap
USD 289M
P/E
31.5x
P/B
5.93x
ROE
-151.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DTIL.US undervalued?

Graham number
Price7.57
Graham value2.63
Premium188.2%

DTIL.US trades 188.2% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Precision BioSciences Inc fundamental analysis

No fundamental analysis for Precision BioSciences Inc yet.

Precision BioSciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Precision BioSciences Inc

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate inte…

Full company profile